Reach Us +44-1753390542
Mesenchymal Stem Cell-Based Immunomodulation in Allogeneic Heterotopic Heart-Lung Transplantation | OMICS International | Abstract
ISSN: 2161-0991

Journal of Transplantation Technologies & Research
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Mesenchymal Stem Cell-Based Immunomodulation in Allogeneic Heterotopic Heart-Lung Transplantation

Biancamaria Longoni1*, Erzsèbet Szilàgyi1, Lorenza Puviani2, Benedetta Mazzanti3, Giacomo Timoteo Paoli1, Serena Urbani3, Paola Quaranta1, Sara Antonini1, Sergio Tripodi4, Marcella Cintorino4, Riccardo Saccardi3, Bruno Nardo2 and Franco Mosca1

1Department of Oncology, Transplantation and New Technology in Medicine, University of Pisa, Pisa, Italy

2Department of Surgery, Bologna University, St. Orsola Hospital, Bologna, Italy

3Bone Marrow Transplant Unit, Hematology Unit, Careggi Hospital, Florence, Italy

4Department of Human Pathology and Oncology, Pathology Section, University of Siena, Siena, Italy

*Corresponding Author:
Prof. Longoni Biancamaria, MD, PhD
Department of Oncology
Transplantation and Advanced Technology in Medicine
University of Pisa, Via Paradisa 2, 56124, Pisa, Italy
Tel: +39050996918
Fax: +39050543692
E-mail: [email protected]

Received Date: October 08, 2011; Accepted Date: December 12, 2011; Published Date: December 17, 2011

Citation: Longoni B, Szilàgyi E, Puviani L, Mazzanti B, Paoli GT, et al. (2012) Mesenchymal Stem Cell-Based Immunomodulation in Allogeneic Heterotopic Heart-Lung Transplantation. J Transplant Technol Res 2: 107. doi: 10.4172/2161-0991.1000107

Copyright: © 2012 Longoni B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Mesenchymal stem cells are able to differentiate in various cell lineages and they have shown immunomodulatory properties in vitro, altering the cytokine secretion profile of T helper, T effector and dendritic cells and stimulating natural killer cells towards an anti-inflammatory and tolerant phenotype. In vivo they prolong skin allograft survival and may decrease graft-versus-host disease after hematopoietic stem cell transplants. In this work we studied the effects of mesenchymal stem cell treatment in an allogeneic heterotopic heart-lung transplant model.

The following experimental groups were formed: A) Control B) Immunosuppressive therapy (Cyclosporine A) C) Mesenchymal stem-cell intravenous infusion D) Mesenchymal stem-cell infusion plus immunosuppressive treatment.

The infusion of mesenchymal stem cells improved the mean graft survival up to 14.5±3.7 days with respect to the control group (3±0.6 days). Treatment with Cyclosporine A plus mesenchymal stem cells (group D) produced a mean survival time of 18.25±4.9 days, and was not significantly different to the results for group B (21.75±3.5 days). Furthermore, in the immunosuppressive treatment and the mesenchymal stem cell treatment, histological analysis revealed a reduction in the grade of rejection in heart and lung grafts. This decrease was most significant in group D.

In conclusion, mesenchymal stem cells alone or in combination with Cyclosporine A were able to prolong graft survival time. These data suggest that, in vivo, mesenchymal stem cells retain their ability, already shown in vitro, to suppress lymphocyte activation and proliferation.

Recommended Conferences

4th Annual Summit on Surgery and Transplantation

Singapore, Singapore

International Congress on Gastroenterology and Liver Transplant

Auckland, New Zealand
Share This Page